Sexual anhedonia

Last updated

Sexual anhedonia, also known as pleasure dissociative orgasmic disorder, is a condition in which an individual cannot feel pleasure (see anhedonia) from an orgasm. It is thought to be a variant of hypoactive sexual desire disorder.

Contents

Overview

Normally, humans feel pleasure from an orgasm; upon reaching a climax, chemicals are released in the brain, and motor signals are activated that will cause quick cycles of muscle contraction in the corresponding areas of both males and females. Sometimes these signals can cause other involuntary muscle contractions, such as body movements and vocalization. Finally, during orgasm, upward neural signals go to the cerebral cortex and feelings of intense pleasure are experienced. People with this disorder are aware of reaching an orgasm, as they can feel the physical effects of it, but they experience very limited or no sort of pleasure. [1]

Causes

It is thought that people with sexual anhedonia have a dysfunction in the release of the chemical dopamine in the nucleus accumbens, the brain's primary reward center. This part of the brain is thought to play a role in pleasurable activities, including laughter, exercise, and music. Additionally, it is thought that depression, drug addiction, high levels of prolactin, low testosterone, and uses of certain medications might play a role in inhibiting dopamine. A spinal cord injury or chronic fatigue syndrome might also occasionally cause this disorder. [2] Age may also be a cause of this disorder. [3]

A sudden-onset sexual anhedonia can also be a symptom of sensory neuropathy, which is most commonly the result of pyridoxine toxicity [4] (e.g., from large doses of vitamin B6 supplements). In this case, the sexual dysfunction promptly resolves spontaneously once the B6 supplementation is stopped.[ citation needed ]

Increased serum prolactin (PRL) [5] concentration in patients' brains from psychiatric medicine can also affect sexuality. [6] Psychiatric medicine is known to cause the brain to form more dopamine receptors for the dopamine blocking effect. The normal amount of dopamine released during sex is insufficient to stimulate the larger number of dopamine receptors. [7] [8] [9] [10] [11]

Treatment

Several treatment methods have been devised to help patients cope. Exploration of psychological factors is one method, which includes exploring past trauma, abuse, and prohibitions in the cultural and religious history of the person. Sex therapy might also be used as a way of helping to realign and examine the patient's expectations of an orgasm. Contributing medical causes must also be ruled out and medications might have to be switched when appropriate. Additionally, blood testing might help determine levels of hormones and other things in the bloodstream that might inhibit pleasure. This condition can also be treated with drugs that increase dopamine, such as oxytocin, along with other drugs. In general, it is recommended that a combination of psychological and physiological treatments should be used to treat the disorder. [12]

Other drugs which may be helpful in the treatment of this condition include dopamine agonists, oxytocin, phosphodiesterase type 5 inhibitors, and alpha-2 receptor blockers like yohimbine. [13]

See also

Related Research Articles

Erectile dysfunction (ED), also referred to as impotence, is a form of sexual dysfunction in males characterized by the persistent or recurring inability to achieve or maintain a penile erection with sufficient rigidity and duration for satisfactory sexual activity. It is the most common sexual problem in males and can cause psychological distress due to its impact on self-image and sexual relationships.

In psychology, libido is psychic drive or energy, usually conceived of as sexual in nature, but sometimes conceived of as including other forms of desire. The term libido was originally developed by Sigmund Freud, the pioneering originator of psychoanalysis. With direct reference to Plato's Eros, the term initially referred only to specific sexual desire, later expanded to the concept of a universal psychic energy that drives all instincts and whose great reservoir is the id. The libido - in its abstract core differentiated partly according to its synthesising, partly to its analytical aspect called life- and death-drive - thus becomes the source of all natural forms of expression: the behaviour of sexuality as well as striving for social commitment, skin pleasure, food, knowledge and victory in the areas of species- and self-preservation.

Orgasm or sexual climax is the sudden release of accumulated sexual excitement during the sexual response cycle, characterized by intense sexual pleasure resulting in rhythmic, involuntary muscular contractions in the pelvic region. Orgasms are controlled by the involuntary or autonomic nervous system and experienced by both males and females; the body's response includes muscular spasms, a general euphoric sensation, and, frequently, body movements and vocalizations. The period after orgasm is typically a relaxing experience, after the release of the neurohormones oxytocin and prolactin, as well as endorphins.

<span class="mw-page-title-main">Anhedonia</span> Inability to feel pleasure

Anhedonia is a diverse array of deficits in hedonic function, including reduced motivation or ability to experience pleasure. While earlier definitions emphasized the inability to experience pleasure, anhedonia is currently used by researchers to refer to reduced motivation, reduced anticipatory pleasure (wanting), reduced consummatory pleasure (liking), and deficits in reinforcement learning. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), anhedonia is a component of depressive disorders, substance-related disorders, psychotic disorders, and personality disorders, where it is defined by either a reduced ability to experience pleasure, or a diminished interest in engaging in previously pleasurable activities. While the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) does not explicitly mention anhedonia, the depressive symptom analogous to anhedonia as described in the DSM-5 is a loss of interest or pleasure.

Anorgasmia is a type of sexual dysfunction in which a person cannot achieve orgasm despite adequate sexual stimulation. Anorgasmia is far more common in females (4.6%) than in males and is especially rare in younger men. The problem is greater in women who are post-menopausal. In males, it is most closely associated with delayed ejaculation. Anorgasmia can often cause sexual frustration.

Premature ejaculation (PE) is a male sexual dysfunction that occurs when a male expels semen soon after beginning sexual activity, and with minimal penile stimulation. It has also been called early ejaculation, rapid ejaculation, rapid climax, premature climax and (historically) ejaculatio praecox. There is no uniform cut-off defining "premature", but a consensus of experts at the International Society for Sexual Medicine endorsed a definition of around one minute after penetration. The International Classification of Diseases (ICD-10) applies a cut-off of 15 seconds from the beginning of sexual intercourse.

<span class="mw-page-title-main">Hyperprolactinaemia</span> Excess of prolactin hormone in the blood

Hyperprolactinaemia is a condition characterized by abnormally high levels of prolactin in the blood. In women, normal prolactin levels average to about 13 ng/mL, while in men, they average 5 ng/mL. The upper normal limit of serum prolactin is typically between 15 to 25 ng/mL for both genders. Levels exceeding this range indicate hyperprolactinemia.

Persistent genital arousal disorder (PGAD), originally called persistent sexual arousal syndrome (PSAS), is spontaneous, persistent, unwanted and uncontrollable genital arousal in the absence of sexual stimulation or sexual desire, and is typically not relieved by orgasm. Instead, multiple orgasms over hours or days may be required for relief.

Hypoactive sexual desire disorder (HSDD), hyposexuality, or inhibited sexual desire (ISD) is sometimes considered a sexual dysfunction, and is characterized as a lack or absence of sexual fantasies and desire for sexual activity, as judged by a clinician. For this to be regarded as a disorder, it must cause marked distress or interpersonal difficulties and not be better accounted for by another mental disorder, a drug, or some other medical condition. A person with ISD will not start, or respond to their partner's desire for, sexual activity. HSDD affects approximately 10% of all pre-menopausal women in the United States, or about 6 million women, 1.5% of men and an unstudied amount of gender non-conforming people.

Sexual dysfunction is difficulty experienced by an individual or partners during any stage of normal sexual activity, including physical pleasure, desire, preference, arousal, or orgasm. The World Health Organization defines sexual dysfunction as a "person's inability to participate in a sexual relationship as they would wish". This definition is broad and is subject to many interpretations. A diagnosis of sexual dysfunction under the DSM-5 requires a person to feel extreme distress and interpersonal strain for a minimum of six months. Sexual dysfunction can have a profound impact on an individual's perceived quality of sexual life. The term sexual disorder may not only refer to physical sexual dysfunction, but to paraphilias as well; this is sometimes termed disorder of sexual preference.

Sexual medicine or psychosexual medicine as defined by Masters and Johnsons in their classic Textbook of Sexual Medicine, is "that branch of medicine that focuses on the evaluation and treatment of sexual disorders, which have a high prevalence rate." Examples of disorders treated with sexual medicine are erectile dysfunction, hypogonadism, and prostate cancer. Sexual medicine often uses a multidisciplinary approach involving physicians, mental health professionals, social workers, and sex therapists. Sexual medicine physicians often approach treatment with medicine and surgery, while sex therapists often focus on behavioral treatments.

Sex and drugs refers to the influence of substances on sexual function and experience. Sex and drugs date back to ancient humans and have been interlocked throughout human history. Sexual performance is known as the execution of the act of sex and the quality of sexual activity. This includes elements such as libido, sexual function, sensation. Drugs are termed as any chemical substance that produces a physiological and or psychological change in an organism. Drugs categorized as psychoactive drugs, antihypertensive drugs, antihistamines, cancer treatment, and hormone medication have a significant impact on sexual performance. Various drugs result in different effects, both positive and negative. Negative effects may include low libido, erection issues, vaginal dryness and anorgasmia. Positive effects usually address these issues, overall enhancing sexual performance and contributing to a more enjoyable sexual experience. It is crucial to know that the impact of drugs on sexual performance varies among individuals, especially among different genders.

Delayed ejaculation (DE) is a man's inability or persistent difficulty in achieving orgasm, despite typical sexual desire and sexual stimulation. Generally, a man can reach orgasm within a few minutes of active thrusting during sexual intercourse, whereas a man with delayed ejaculation either does not have orgasms at all or cannot have an orgasm until after prolonged intercourse which might last for 30–45 minutes or more. Delayed ejaculation is closely related to anorgasmia.

<span class="mw-page-title-main">Flibanserin</span> Medication

Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. The most common side effects are dizziness, sleepiness, nausea, difficulty falling asleep or staying asleep and dry mouth.

Postorgasmic illness syndrome (POIS) is a syndrome in which human males have chronic physical and cognitive symptoms following ejaculation. The symptoms usually onset within seconds, minutes, or hours, and last for up to a week. The cause and prevalence are unknown; it is considered a rare disease.

<span class="mw-page-title-main">Lodenafil</span> Chemical compound

Lodenafil is a drug belonging to a class of drugs called PDE5 inhibitor, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. Like udenafil and avanafil it belongs to a new generation of PDE5 inhibitors.

<span class="mw-page-title-main">Norepinephrine–dopamine disinhibitor</span> Antidepressant

A norepinephrine and dopamine disinhibitor is a drug that acts at specific sites to disinhibit downstream norepinephrine and dopamine release in the brain.

<span class="mw-page-title-main">Hypoprolactinemia</span> Medical condition

Hypoprolactinemia is a medical condition characterized by a deficiency in the serum levels of the hypothalamic-pituitary hormone prolactin.

<span class="mw-page-title-main">Nipple stimulation</span> Human sexual practice

Nipple stimulation or breast stimulation is stimulation of the breast. Stimulation may be by breastfeeding, sexual activity, an indirect non-sexual response, or kissing the nipple. As part of sexual activity, the practice may be performed upon, or by, people of any gender or sexual orientation. It may occur with the use of fingers, orally, such as by sucking or licking, as well as by use of an object.

Drugs and sexual desire is about sexual desire being manipulated through drugs from various approaches. Sexual desire is generated under the effects from sex hormones and microcircuits from brain regions. Neurotransmitters play essential roles in stimulating and inhibiting the processes that lead to libido production in both men and women. For instance, a positive stimulation is modulated by dopamine from the medial preoptic area in the hypothalamus and norepinephrine. At the same time, inhibition occurs when prolactin and serotonin are released for action.

References

  1. Perelman MA (2011). "Anhedonia/PDOD: Overview". The Institute For Sexual Medicine. Retrieved 14 February 2011.[ dead link ]
  2. Perelman MA (2011). "Anhedonia/PDOD: Causes". The Institute For Sexual Medicine. Archived from the original on April 15, 2013. Retrieved 14 February 2011.
  3. Comprehensive Textbook of Sexual Medicine By Kar, page 18
  4. Schaumburg, Herbert; Kaplan, Jerry; Windebank, Anthony; Vick, Nicholas; Rasmus, Stephen; Pleasure, David; Brown, Mark J. (1983). "Sensory Neuropathy from Pyridoxine Abuse — A New Megavitamin Syndrome - NEJM". New England Journal of Medicine. 309 (8): 445–448. doi:10.1056/nejm198308253090801. PMID   6308447.
  5. Peuskens J, Pani L, Detraux J, De Hert M (May 2014). "The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review". CNS Drugs. 28 (5): 421–53. doi:10.1007/s40263-014-0157-3. PMC   4022988 . PMID   24677189.
  6. Konarzewska B, Szulc A, Popławska R, Galińska B, Juchnowicz D (2008). "[Impact of neuroleptic-induced hyperprolactinemia on sexual dysfunction in male schizophrenic patients]". Psychiatria Polska. 42 (1): 87–95. PMID   18567406.
  7. Whitaker L, Cooper S (10 July 2014). Pharmacological Treatment of College Students with Psychological Problems. Routledge. ISBN   9781317954453 . Retrieved 17 April 2018 via Google Books.
  8. Tupala E, Haapalinna A, Viitamaa T, Männistö PT, Saano V (June 1999). "Effects of repeated low dose administration and withdrawal of haloperidol on sexual behaviour of male rats". Pharmacology & Toxicology. 84 (6): 292–5. doi:10.1111/j.1600-0773.1999.tb01497.x. PMID   10401732.
  9. Martin-Du Pan R (1978). "[Neuroleptics and sexual dysfunction in man. Neuroendocrine aspects]". Schweizer Archiv für Neurologie, Neurochirurgie und Psychiatrie = Archives Suisses de Neurologie, Neurochirurgie et de Psychiatrie (in French). 122 (2): 285–313. PMID   29337.
  10. Dominguez, Juan M.; Hull, Elaine M. (2005). "Download Limit Exceeded". Physiol. Behav. 86 (3): 356–368. CiteSeerX   10.1.1.325.3090 . doi:10.1016/j.physbeh.2005.08.006. PMID   16135375. S2CID   12493855.
  11. de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H (May 2015). "The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings". Schizophrenia Bulletin. 41 (3): 674–86. doi:10.1093/schbul/sbv001. PMC   4393701 . PMID   25721311.
  12. Perelman MA (2011). "Anhedonia/PDOD: Treatment". The Institute For Sexual Medicine. Archived from the original on 23 July 2010. Retrieved 14 February 2011.
  13. Goldstein I. "Orgasmic Anhedonia/ PDOD: Treatment". The Institute for Sexual Medicine. Archived from the original on 5 July 2013. Retrieved 15 July 2014.

Bibliography